Metabotropic glutamate receptors in the basal ganglia motor circuit

In recent years there have been tremendous advances in our understanding of the circuitry of the basal ganglia and our ability to predict the behavioural effects of specific cellular changes in this circuit on voluntary movement. These advances, combined with a new understanding of the rich distribution and diverse physiological roles of metabotropic glutamate receptors in the basal ganglia, indicate that these receptors might have a key role in motor control and raise the exciting possibility that they might provide therapeutic targets for the treatment of Parkinson's disease and related disorders.

[1]  Feng Liu,et al.  Mechanism of Regulation of Casein Kinase I Activity by Group I Metabotropic Glutamate Receptors* , 2002, The Journal of Biological Chemistry.

[2]  P. Popoli,et al.  Permissive role of adenosine A2A receptors on metabotropic glutamate receptor 5 (mGluR5)‐mediated effects in the striatum , 2004, Journal of neurochemistry.

[3]  Y. Smith,et al.  NMDA-induced phosphorylation and regulation of mGluR5 , 2002, Pharmacology Biochemistry and Behavior.

[4]  Charles J. Wilson,et al.  Striatal interneurones: chemical, physiological and morphological characterization , 1995, Trends in Neurosciences.

[5]  P. Worley,et al.  Coupling of mGluR/Homer and PSD-95 Complexes by the Shank Family of Postsynaptic Density Proteins , 1999, Neuron.

[6]  J. Bargas,et al.  Cholinergic Modulation of Neostriatal Output: a Functional Antagonism between Different Types of Muscarinic Receptors Materials and Methods , 1999 .

[7]  D. Lovinger.  Trans-1-aminocyclopentane-1,3-dicarboxylic acid (t-ACPD) decreases synaptic excitation in rat striatal slices through a presynaptic action , 1991, Neuroscience Letters.

[8]  S. Heinemann,et al.  Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems , 1999, Nature Neuroscience.

[9]  P. Calabresi,et al.  The modulation of calcium currents by the activation of mGluRs , 1996, Molecular Neurobiology.

[10]  P. Calabresi,et al.  Long-term synaptic depression in the striatum: physiological and pharmacological characterization , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[11]  B Bioulac,et al.  Subthalamic Nucleus Neurons Switch from Single-Spike Activity to Burst-Firing Mode , 1999, The Journal of Neuroscience.

[12]  Y. Kawaguchi,et al.  Physiological, morphological, and histochemical characterization of three classes of interneurons in rat neostriatum , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[13]  P Jeffrey Conn,et al.  Group III Metabotropic Glutamate Receptor-Mediated Modulation of the Striatopallidal Synapse , 2003, The Journal of Neuroscience.

[14]  S. Duty,et al.  Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine‐treated rat , 2004, British journal of pharmacology.

[15]  P. Greengard,et al.  D(2) dopamine receptors induce mitogen-activated protein kinase and cAMP response element-binding protein phosphorylation in neurons. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[16]  G. V. van Rossum,et al.  A 6-year follow-up study of oral function in shortened dental arches. Part II: Craniomandibular dysfunction and oral comfort. , 1994, Journal of oral rehabilitation.

[17]  F. Gasparini,et al.  Selective Activation of mGlu4 Metabotropic Glutamate Receptors Is Protective against Excitotoxic Neuronal Death , 2000, The Journal of Neuroscience.

[18]  T. Hastings,et al.  Biomedicine. Parkinson's--divergent causes, convergent mechanisms. , 2004, Science.

[19]  M. Beal,et al.  Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Beal,et al.  Experimental therapeutics in transgenic mouse models of Huntington's disease , 2004, Nature Reviews Neuroscience.

[21]  F. Nicoletti,et al.  Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice , 2003, Neuropharmacology.

[22]  W. Maragos,et al.  Neuronal cell death in Huntington’s disease: a potential role for dopamine , 2000, Trends in Neurosciences.

[23]  M. Beal,et al.  Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington’s Disease , 1996, The Journal of Neuroscience.

[24]  F. Nicoletti,et al.  Interactions between Ephrin-B and Metabotropic Glutamate 1 Receptors in Brain Tissue and Cultured Neurons , 2005, The Journal of Neuroscience.

[25]  A. Levey,et al.  Striatal dopamine nerve terminal markers in human, chronic methamphetamine users , 1996, Nature Medicine.

[26]  G. Nappi,et al.  Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease , 2001, Annals of neurology.

[27]  F. Nicoletti,et al.  Neuroprotection by Glial Metabotropic Glutamate Receptors Is Mediated by Transforming Growth Factor-β , 1998, The Journal of Neuroscience.

[28]  S. Traynelis,et al.  Metabotropic Glutamate Receptors 1 and 5 Differentially Regulate CA1 Pyramidal Cell Function , 2001, The Journal of Neuroscience.

[29]  M. Morari,et al.  Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group‐II metabotropic and NMDA receptors , 2003, Journal of neurochemistry.

[30]  P. Calabresi,et al.  The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia , 1996, Trends in Neurosciences.

[31]  P Jeffrey Conn,et al.  Modulation of the basal ganglia by metabotropic glutamate receptors: potential for novel therapeutics. , 2002, Current drug targets. CNS and neurological disorders.

[32]  A. Charara,et al.  GABAB and group I metabotropic glutamate receptors in the striatopallidal complex in primates , 2000, Journal of anatomy.

[33]  S. T. Kitai,et al.  Firing patterns and synaptic potentials of identified giant aspiny interneurons in the rat neostriatum , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[34]  J. Schiefer,et al.  The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease , 2004, Brain Research.

[35]  L. Mao,et al.  Selective activation of group I metabotropic glutamate receptors upregulates preprodynorphin, substance P, and preproenkephalin mRNA expression in rat dorsal striatum , 2001, Synapse.

[36]  Y. Ben-Ari,et al.  Quisqualate Metabotropic Receptors Modulate NMDA Currents and Facilitate Induction of Long‐Term Potentiation Through Protein Kinase C , 1992, The European journal of neuroscience.

[37]  J. T. Greenamyre,et al.  Parkinson's--Divergent Causes, Convergent Mechanisms , 2004, Science.

[38]  F. Nicoletti,et al.  Metabotropic Glutamate Receptor Subtypes as Targets for Neuroprotective Drugs , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[39]  J. Cano,et al.  Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+‐induced neurotoxicity along with brain‐derived neurotrophic factor induction , 2001, Journal of neurochemistry.

[40]  P. Greengard,et al.  Dopamine and cAMP-Regulated Phosphoprotein 32 kDa Controls Both Striatal Long-Term Depression and Long-Term Potentiation, Opposing Forms of Synaptic Plasticity , 2000, The Journal of Neuroscience.

[41]  M. Merello,et al.  Functional surgery for Parkinson's disease treatment: a structured analysis of a decade of published literature , 2004, British journal of neurosurgery.

[42]  W. Spooren,et al.  Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats. , 2000, European journal of pharmacology.

[43]  M R DeLong,et al.  Models of basal ganglia function and pathophysiology of movement disorders. , 1998, Neurosurgery clinics of North America.

[44]  K. Lange,et al.  Glutamatergic drugs in Parkinson's disease. , 1994, Life sciences.

[45]  K. Fuxe,et al.  Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: Implications for striatal neuronal function , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Y. Smith,et al.  Distinct Functional Roles of the Metabotropic Glutamate Receptors 1 and 5 in the Rat Globus Pallidus , 2003, The Journal of Neuroscience.

[47]  R. Albin,et al.  Metabotropic Glutamate Agonist-Induced Rotation: A Pharmacological, FOS Immunohistochemical, and [14C]-2-Deoxyglucose Autoradiographic Study , 1997, The Journal of Neuroscience.

[48]  D. Lovinger,et al.  Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGLuR2 or 3. , 1995, Journal of neurophysiology.

[49]  P. Calabresi,et al.  Selective involvement of mGlu1 receptors in corticostriatal LTD , 2001, Neuropharmacology.

[50]  P. Conn,et al.  Distinct physiological roles of the Gq‐coupled metabotropic glutamate receptors co‐expressed in the same neuronal populations , 2002, Journal of cellular physiology.

[51]  B. Hyman,et al.  Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: A stereological estimate of neuronal loss , 1993, Neurobiology of Aging.

[52]  O. Hassani,et al.  Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states , 1997, Neuroscience.

[53]  D. Standaert,et al.  Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[54]  P. Conn,et al.  Activation of group III mGluRs inhibits GABAergic and glutamatergic transmission in the substantia nigra pars reticulata. , 2001, Journal of neurophysiology.

[55]  J. Pin,et al.  Pharmacology and functions of metabotropic glutamate receptors. , 1997, Annual review of pharmacology and toxicology.

[56]  F. Nicoletti,et al.  Neuroprotective activity of the potent and selective mGlu1a metabotropic glutamate receptor antagonist, (+)-2-methyl-4 carboxyphenylglycine (LY367385): comparison with LY357366, a broader spectrum antagonist with equal affinity for mGlu1a and mGlu5 receptors , 1999, Neuropharmacology.

[57]  V. Lee,et al.  Are Ubiquitination Pathways Central to Parkinson's Disease? , 2003, Cell.

[58]  I. Vranesic,et al.  (−)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection , 2003, Neuropharmacology.

[59]  Giuseppe Battaglia,et al.  Endogenous Activation of mGlu5 Metabotropic Glutamate Receptors Contributes to the Development of Nigro-Striatal Damage Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in Mice , 2004, The Journal of Neuroscience.

[60]  Roland Heckendorn,et al.  2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist , 1999, Neuropharmacology.

[61]  M. O'Neill,et al.  Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease , 2002, Pharmacology Biochemistry and Behavior.

[62]  P. Calabresi,et al.  Targeting striatal cholinergic interneurons in Parkinson’s disease: Focus on metabotropic glutamate receptors , 2003, Neuropharmacology.

[63]  J. Penney,et al.  The Role of Group I and Group II Metabotropic Glutamate Receptors in Modulation of Striatal NMDA and Quinolinic Acid Toxicity , 2001, Experimental Neurology.

[64]  P. Conn,et al.  Group III Metabotropic Glutamate-Receptor-Mediated Modulation of Excitatory Transmission in Rodent Substantia Nigra Pars Compacta Dopamine Neurons , 2005, Journal of Pharmacology and Experimental Therapeutics.

[65]  Andrzej Pilc,et al.  LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats , 1998, Naunyn-Schmiedeberg's Archives of Pharmacology.

[66]  L. Seiden,et al.  Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine , 1980, Brain Research.

[67]  P. Calabresi,et al.  Post-receptor mechanisms underlying striatal long-term depression , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[68]  L. Mao,et al.  Group I metabotropic glutamate receptor‐mediated calcium signalling and immediate early gene expression in cultured rat striatal neurons , 2003, The European journal of neuroscience.

[69]  D. Schoepp,et al.  In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats , 1997, Neuroscience Letters.

[70]  K. Mangano,et al.  Activation of Group III Metabotropic Glutamate Receptors Inhibits the Production of RANTES in Glial Cell Cultures , 2002, The Journal of Neuroscience.

[71]  L. Mao,et al.  The protein phosphatase 1/2A inhibitor okadaic acid increases CREB and Elk‐1 phosphorylation and c‐fos expression in the rat striatum in vivo , 2004, Journal of neurochemistry.

[72]  P. Conn,et al.  Dopamine Modulates the Function of Group II and Group III Metabotropic Glutamate Receptors in the Substantia Nigra Pars Reticulata , 2002, Journal of Pharmacology and Experimental Therapeutics.

[73]  B. Hyman,et al.  Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[74]  S. Duty,et al.  The group II metabotropic glutamate receptor agonist, DCG‐IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine‐treated rat , 2000, British journal of pharmacology.

[75]  G. Collingridge,et al.  Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1 , 1994, Nature.

[76]  A. Charara,et al.  Ionotropic and metabotropic GABA and glutamate receptors in primate basal ganglia , 2001, Journal of Chemical Neuroanatomy.

[77]  G. Collingridge,et al.  Signal transduction pathways involved in the acute potentiation of NMDA responses by 1S,3R‐ACPD in rat hippocampal slices , 1993, British journal of pharmacology.

[78]  Benjamin L Walter,et al.  Surgical treatment for Parkinson's disease , 2004, The Lancet Neurology.

[79]  Zheng-Xiong Xi,et al.  The Origin and Neuronal Function of In Vivo Nonsynaptic Glutamate , 2002, The Journal of Neuroscience.

[80]  F. Moroni,et al.  Type 2 Metabotropic Glutamate (mGlu) Receptors Tonically Inhibit Transmitter Release in Rat Caudate Nucleus: In Vivo Studies with (2S,1′S,2′S,3′R)‐2‐(2′‐carboxy‐3′‐phenylcyclopropyl)glycine, a New Potent and Selective Antagonist , 1997, The European journal of neuroscience.

[81]  A. Dilella,et al.  Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[82]  K. Kullander,et al.  Mechanisms and functions of eph and ephrin signalling , 2002, Nature Reviews Molecular Cell Biology.

[83]  H. Kita,et al.  Activation of group III metabotropic glutamate receptors presynaptically reduces both GABAergic and glutamatergic transmission in the rat globus pallidus , 2003, Neuroscience.

[84]  F. Gasparini,et al.  Neuroprotective activity of metabotropic glutamate receptor ligands. , 2002, Advances in experimental medicine and biology.

[85]  S. W. Davies,et al.  Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[86]  Y. Smith,et al.  Activation of Group I Metabotropic Glutamate Receptors Produces a Direct Excitation and Disinhibition of GABAergic Projection Neurons in the Substantia Nigra Pars Reticulata , 2001, The Journal of Neuroscience.

[87]  J. Penney,et al.  Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons , 1995, The Journal of comparative neurology.

[88]  M. Amalric,et al.  Simultaneous Blockade of Adenosine A2A and Metabotropic Glutamate mGlu5 Receptors Increase their Efficacy in Reversing Parkinsonian Deficits in Rats , 2004, Neuropsychopharmacology.

[89]  K. Fuxe,et al.  Protection but maintained dysfunction of nigral dopaminergic nerve cell bodies and striatal dopaminergic terminals in MPTP-lesioned mice after acute treatment with the mGluR5 antagonist MPEP , 2005, Brain Research.

[90]  P. Greengard,et al.  Regulation of cyclin-dependent kinase 5 and casein kinase 1 by metabotropic glutamate receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[91]  Antonio Pisani,et al.  Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases , 2004, Progress in Neurobiology.

[92]  D. S. Albers,et al.  Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism , 2005, Amino Acids.

[93]  J. Cano,et al.  DCG-IV but not other group-II metabotropic receptor agonists induces microglial BDNF mRNA expression in the rat striatum. Correlation with neuronal injury , 2002, Neuroscience.

[94]  Roger L Albin,et al.  Localization of mGluR1a-like immunoreactivity and mGluR5-like immunoreactivity in identified populations of striatal neurons , 1998, Brain Research.

[95]  M. Amalric,et al.  Chronic But Not Acute Treatment with a Metabotropic Glutamate 5 Receptor Antagonist Reverses the Akinetic Deficits in a Rat Model of Parkinsonism , 2002, The Journal of Neuroscience.

[96]  J. T. Greenamyre,et al.  Bioenergetics and glutamate excitotoxicity , 1996, Progress in Neurobiology.

[97]  D. Laurie,et al.  (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. , 1999, The Journal of pharmacology and experimental therapeutics.

[98]  P. Calabresi,et al.  Metabotropic Glutamate 2 Receptors Modulate Synaptic Inputs and Calcium Signals in Striatal Cholinergic Interneurons , 2002, The Journal of Neuroscience.

[99]  M. Beal,et al.  Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia , 1997, Annals of neurology.

[100]  D. Standaert,et al.  Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGluR2/3 in the rat basal ganglia , 1998, The Journal of comparative neurology.

[101]  D. Lovinger,et al.  Postsynaptic endocannabinoid release is critical to long-term depression in the striatum , 2002, Nature Neuroscience.

[102]  P. Calabresi,et al.  Endogenous ACh enhances striatal NMDA‐responses via M1‐like muscarinic receptors and PKC activation , 1998, The European journal of neuroscience.

[103]  R. Albin,et al.  The role of nigrostriatal dopamine in metabotropic glutamate agonist-induced rotation , 1998, Neuroscience.

[104]  W. Poewe,et al.  Low‐dose L‐dopa therapy in Parkinson's disease , 1986, Neurology.

[105]  Greenamyre Jt,et al.  Bioenergetics and glutamate excitotoxicity. , 1996 .

[106]  G. Battaglia,et al.  Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective , 2000, Neuropharmacology.

[107]  K. Perry,et al.  Dopamine and 5-HT turnover are increased by the mGlu2/3 receptor agonist LY379268 in rat medial prefrontal cortex, nucleus accumbens and striatum , 2000, Brain Research.

[108]  M. Delong,et al.  Functional and pathophysiological models of the basal ganglia , 1996, Current Opinion in Neurobiology.

[109]  Y. Smith,et al.  Differential Subcellular Localization of mGluR1a and mGluR5 in the Rat and Monkey Substantia Nigra , 2001, The Journal of Neuroscience.

[110]  G. Nappi,et al.  Blockade of subthalamic glutamatergic activity corrects changes in neuronal metabolism and motor behavior in rats with nigrostriatal lesions , 2001, Neurological Sciences.

[111]  D. Plenz,et al.  Regulation of the Nigrostriatal Pathway by Metabotropic Glutamate Receptors during Development , 1998, The Journal of Neuroscience.

[112]  F. Nicoletti,et al.  Selective Blockade of mGlu5 Metabotropic Glutamate Receptors Is Protective against Methamphetamine Neurotoxicity , 2002, The Journal of Neuroscience.

[113]  P. Greengard,et al.  Inhibition of Mitochondrial Complex II Induces a Long-Term Potentiation of NMDA-Mediated Synaptic Excitation in the Striatum Requiring Endogenous Dopamine , 2001, The Journal of Neuroscience.

[114]  D. Lovinger,et al.  Activation of group I mGluRs is necessary for induction of long-term depression at striatal synapses. , 2001, Journal of neurophysiology.

[115]  P. Greengard,et al.  Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[116]  R. Porter,et al.  Inhibition of Succinate Dehydrogenase by Malonic Acid Produces an “Excitotoxic” Lesion in Rat Striatum , 1993, Journal of neurochemistry.

[117]  S. Hyman,et al.  Addiction and the brain: The neurobiology of compulsion and its persistence , 2001, Nature Reviews Neuroscience.

[118]  P. Conn,et al.  Activation of groups I or III metabotropic glutamate receptors inhibits excitatory transmission in the rat subthalamic nucleus , 2001, Neuropharmacology.

[119]  J. Grutsch,et al.  Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. , 1999, Journal of medicinal chemistry.

[120]  J. Cooper,et al.  Mitochondrial defect in Huntington's disease caudate nucleus , 1996, Annals of neurology.

[121]  P. Löschmann,et al.  Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists , 1991, Nature.

[122]  M. Amalric,et al.  Metabotropic Glutamate 5 Receptor Blockade Alleviates Akinesia by Normalizing Activity of Selective Basal-Ganglia Structures in Parkinsonian Rats , 2003, The Journal of Neuroscience.

[123]  F. Gasparini,et al.  SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. , 1999, The Journal of pharmacology and experimental therapeutics.

[124]  D. Lovinger,et al.  Decreased Frequency But Not Amplitude of Quantal Synaptic Responses Associated with Expression of Corticostriatal Long-Term Depression , 1997, The Journal of Neuroscience.

[125]  Y. Smith,et al.  Activation of Metabotropic Glutamate Receptor 5 Has Direct Excitatory Effects and Potentiates NMDA Receptor Currents in Neurons of the Subthalamic Nucleus , 2000, The Journal of Neuroscience.

[126]  G Bernardi,et al.  Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons , 2001, Neuroscience.

[127]  Charles J. Wilson,et al.  The origins of two-state spontaneous membrane potential fluctuations of neostriatal spiny neurons , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[128]  Hui Zhang,et al.  Glutamate Spillover in the Striatum Depresses Dopaminergic Transmission by Activating Group I Metabotropic Glutamate Receptors , 2003, The Journal of Neuroscience.

[129]  F. Nicoletti,et al.  The Neuroprotective Activity of Group-II Metabotropic Glutamate Receptors Requires New Protein Synthesis and Involves a Glial–Neuronal Signaling , 1997, The Journal of Neuroscience.

[130]  J. Pin,et al.  The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. , 2002, Current drug targets. CNS and neurological disorders.

[131]  P. Popoli,et al.  Neuroprotective effects of the mGlu5R antagonist MPEP towards quinolinic acid‐induced striatal toxicity: involvement of pre‐ and post‐synaptic mechanisms and lack of direct NMDA blocking activity , 2004, Journal of neurochemistry.

[132]  P. Conn,et al.  Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders. , 2000, Pharmacology & therapeutics.

[133]  P. Conn,et al.  Haloperidol-induced alteration in the physiological actions of group I mGlus in the subthalamic nucleus and the substantia nigra pars reticulata , 2002, Neuropharmacology.

[134]  J. Sweatt,et al.  The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory , 2001, Journal of neurochemistry.

[135]  C. Fiorillo,et al.  Glutamate mediates an inhibitory postsynaptic potential in dopamine neurons , 1998, Nature.

[136]  F. Vaglini,et al.  (+)MK-801 prevents the DDC-induced enhancement of MPTP toxicity in mice , 1994, Brain Research.

[137]  T. Dawson,et al.  The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders , 2001, Trends in Neurosciences.

[138]  P. Calabresi,et al.  Selective Blockade of Type-1 Metabotropic Glutamate Receptors Induces Neuroprotection by Enhancing Gabaergic Transmission , 2001, Molecular and Cellular Neuroscience.

[139]  F. Nicoletti,et al.  Retracted: Neuroprotection mediated by glial group‐II metabotropic glutamate receptors requires the activation of the MAP kinase and the phosphatidylinositol‐3‐kinase pathways , 2001, Journal of neurochemistry.

[140]  P. Calabresi,et al.  Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment. , 2002, Brain : a journal of neurology.

[141]  P. Somogyi,et al.  Distribution and synaptic localisation of the metabotropic glutamate receptor 4 (mGluR4) in the rodent CNS , 2002, Neuroscience.

[142]  A. Levey,et al.  Activation of Group II Metabotropic Glutamate Receptors Inhibits Synaptic Excitation of the Substantia Nigra Pars Reticulata , 2000, The Journal of Neuroscience.

[143]  P Jeffrey Conn,et al.  Glutamate Receptors and Parkinson’s Disease , 2003, Drugs & aging.

[144]  G. Page,et al.  Modulation of the neuronal dopamine transporter activity by the metabotropic glutamate receptor mGluR5 in rat striatal synaptosomes through phosphorylation mediated processes , 2001, Journal of neurochemistry.

[145]  M. G. Lacey,et al.  Metabotropic glutamate receptors depress glutamate‐mediated synaptic input to rat midbrain dopamine neurones in vitro , 1998, British journal of pharmacology.

[146]  P. Calabresi,et al.  Electrophysiological evidence for the presence of ionotropic and metabotropic excitatory amino acid receptors on dopaminergic neurons of the rat mesencephalon: an in vitro study. , 1992, Functional neurology.

[147]  M. Pietraszek,et al.  The role of metabotropic glutamate receptors in regulation of striatal proenkephalin expression: implications for the therapy of Parkinson′s disease , 2003, Neuroscience.